Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia

Lee, Mi Suk; Oh, Jee Youn; Kang, Cheol-In; Kim, Eu Suk; Park, Sunghoon; Rhee, Chin Kook; Jung, Ji Ye; Jo, Kyung‐Wook; Heo, Eun Young; Park, Dong Ah; Suh, Gee Young; Kiem, Sungmin

doi:10.3947/ic.2018.50.2.160

Cited by 48 publications

(52 citation statements)

References 235 publications

(319 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Then, 88 out of 4125 references were identified for possible inclusion, after 23 duplicated were removed, 38 papers were excluded (Figure ). Accordingly, 18 publications met our inclusion criteria …”

Section: Resultsmentioning

confidence: 99%

“…About the 18 CPGs selected: there is an American guideline (IDSA), one is from Brazil, one from Italy (Gulf), one from India, two European (ERS and Multidisciplinary), two from Spain (SEPAR and Andalusian), a Peruvian guideline, a Dutch guideline (SWAB), two British guidelines (NICE and BTS), a Lebanese guideline, one from Latin America (Consensur), one Colombian guideline, one Chinese, one Korean and one Swedish …”

Section: Resultsmentioning

confidence: 99%

“…The mean score for this domain was 43% (range 0%‐100%). Only six guidelines scored over the cut‐off NICE, IDSA, India, Consensur, Peruvian and the Korean …”

Section: Resultsmentioning

confidence: 99%

“…Accordingly, 18 publications met our inclusion criteria. [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] As shown in Figure 1, the reason for exclusion were as follows:…”

Section: Re Sultsmentioning

confidence: 99%

See 3 more Smart Citations

Clinical practice guidelines for the management of community‐acquired pneumonia: A critical appraisal using the AGREE II instrument

et al. 2020

View full text Add to dashboard Cite

Summary Objective The aim of this study was to appraise the methodological quality of published clinical practice guidelines (CPGs) of community‐acquired pneumonia (CAP) using AGREE II instrument for further enhancing the CAP CPG development. Methods We performed a systematic review of published CPGs on CAP from January 2007 to May 2019. All reviewers independently assessed each CPG using the AGREE II instrument. A standardised score was calculated for each of the six domains. Results Our search strategy identified 4125 citations but just 18 met our inclusion criteria. Agreement among reviewers was very good: 0.98. The domains that scored better were: “scope and purpose” and “clarity and presentation”. Those that scored worse were “editorial independence”, and “applicability”. According to the AGREE II evaluation for each Guideline, the NICE, IDSA, BTS, SWAB, Korea, Consensur II, Colombian and Peruvian CPGs were the only recommended with no further modifications. In addition, ERS and SEPAR CPGs were recommended with modifications, with lower scores regarding the editorial independence and applicability. Conclusion In conclusion, published CPGs for CAP management vary in quality with a need to improve the methodological and applicability rigour. This could be achieved following the standards for guidelines development and a better emphasis on how to apply CPGs recommendations in clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…The mean score for this domain was 43% (range 0%‐100%). Only six guidelines scored over the cut‐off NICE, IDSA, India, Consensur, Peruvian and the Korean …”

Section: Resultsmentioning

confidence: 99%

Section: Re Sultsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical practice guidelines for the management of community‐acquired pneumonia: A critical appraisal using the AGREE II instrument

et al. 2020

View full text Add to dashboard Cite

show abstract

“…TREATMENT Antibiotic treatment is recommended for all patients with CAP, including outpatients [1,10,[52][53][54][55][56]. Treatment success relies on prompt delivery of antibiotics, adapted to the likely causative organisms and clinical severity.…”

Section: Diagnosis and Risk Stratificationmentioning

confidence: 99%

Outpatient management of community-acquired pneumonia

Froes

Pereira

Póvoa

2019

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin

et al. 2020

View full text Add to dashboard Cite

Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality both in the USA and globally. As the burden of CAP continues to increase due to several factors, the advances in its diagnosis, prevention, and treatment have taken on even greater interest and importance. The majority of CAP patients are treated empirically, and selection of appropriate antibiotic treatment is increasingly difficult because the epidemiology of CAP is changing, in part due to antimicrobial resistance, and the causative CAP pathogens differ between countries and regions. There is also an increasing prevalence of chronic co-morbid diseases among CAP patients. Treatment of CAP has become challenging because of these factors along with the varying safety profiles and efficacy of well-established antibiotics, as well as limited new therapeutic options. Recently, however, new antibiotics have been approved, which will expand the treatment options for CAP, particularly in those patients with underlying complications. Recently approved delafloxacin, an anionic fluoroquinolone, has a unique structure and distinct chemical characteristics; it demonstrated non-inferiority to moxifloxacin in a phase III clinical trial, but was shown to be superior to moxifloxacin at early clinical response in CAP patients who also have chronic obstructive pulmonary disease (COPD) or asthma as a co-morbidity, and in CAP patients who may have severe illness. Delafloxacin could offer an additional therapy against resistant isolates and among these difficult-to-treat patients. This review summarizes the development, latest research, and safety profile of the new antibiotic delafloxacin, and its potential future role in the treatment of CAP.

show abstract

Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia

Cited by 48 publications

References 235 publications

Clinical practice guidelines for the management of community‐acquired pneumonia: A critical appraisal using the AGREE II instrument

Clinical practice guidelines for the management of community‐acquired pneumonia: A critical appraisal using the AGREE II instrument

Outpatient management of community-acquired pneumonia

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin

Contact Info

Product

Resources

About